Clinical Trial Update: Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II study evaluating the combination of vebreltinib with furmonertinib for non-small cell lung cancer with c-Met amplification after EGFR-TKI failure; c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)
• Vebreltinib (vebreltinib)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Non Small Cell Lung Cancer NSCLC | Phase 1, Phase 2 | Status: RECRUITING